Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

RAPT vs VRDN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

VRDN Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 5–4 Matrix Metrics)

VRDN Overall Winner 6-Pillar Tally: RAPT 1 – 4 VRDN (1 Tie) Matrix Metrics: RAPT 4 – 5 VRDN

As of Nov 16, 2026, Viridian Therapeutics, Inc. (VRDN) is the stronger overall head-to-head candidate over RAPT Therapeutics, Inc. (RAPT) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). RAPT carries a Unified Composite Score of 52.4/100 (HOLD) at $58.02 (N/M Forward P/E, 0.0% operating margin), whereas VRDN carries 36.8/100 (SELL) at $30.36 (1.0x Forward P/E, -1781.4% operating margin).

  • Composite vs. Pillar Nuance: While RAPT currently prints a higher short-term Unified Composite Score (52.4/100 HOLD vs. VRDN 36.8/100 SELL), VRDN captures the overall institutional head-to-head verdict (5–4 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-1781.4% vs. 0.0% operating margin) and revenue trajectory (-63.5% vs. -100.0% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About RAPT vs VRDN
RAPT NASDAQ
RAPT Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$58.02
+0.07% 1D
Market Cap $1.7B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -0.02β · 2% Vol
Unified Composite Score
52.4 / 100 HOLD
Tech 40.0 Fund 46.0 Flow 61.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (27.1% over 20 days), RSI 80
RSI-14: 79.7 · SMA20: $57.82 · SMA50: $47.67
VRDN NASDAQ Head-to-Head Winner
Viridian Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$30.36
-1.64% 1D
Market Cap $3.5B
TTM Revenue $26M
Forward P/E 1.0x
Beta / 30D Vol 1.13β · 65% Vol
Unified Composite Score
36.8 / 100 SELL
Tech 50.0 Fund 32.0 Flow 65.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (6.0% over 20 days), RSI 72
RSI-14: 72.2 · SMA20: $26.61 · SMA50: $22.89

6-Pillar Scorecard Institutional Category Breakdown (RAPT 1 – 4 VRDN)

Columns: Metric · RAPT · VRDN
1. Valuation Multiples VRDN
Forward P/E N/M 1.0x
Trailing P/E N/M 1.0x
PEG Ratio N/M N/M
EV / Revenue N/M 134.2x
2. Growth & Scale VRDN
Revenue Growth (YoY) -100.0% -63.5%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $26M
Market Cap $1.7B $3.5B
3. Profitability & Quality RAPT
Gross Margin N/A N/A
Operating Margin 0.0% -1781.4%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -85.4% -83.7%
4. Balance Sheet & Cash Flow VRDN
Cash Generation (TTM) N/A -$353M
Cash Flow Margin N/A N/A
Net Cash / Leverage $9.02 Book/Sh · -85.4% ROE $70M Net Debt (0.42x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning VRDN
Options Structure Phase UNCLASSIFIED SURGE
Current IV / %ile 0.8% (<1st %ile) 87.7% (20th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup ACCUMULATION · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: RAPT (4) vs VRDN (5)
Institutional Metric RAPT VRDN Criterion Row Edge
Market Capitalization
Scale
$1.7B $3.5B Larger Scale VRDN
Trailing P/E Ratio
Valuation
N/M 1.0x Lower Multiple VRDN
Forward P/E Ratio
Valuation
N/M 1.0x Lower Multiple VRDN
Revenue Growth (YoY)
Growth
-100.0% -63.5% Higher Growth VRDN
Operating Margin (TTM)
Profitability
0.0% -1781.4% Higher Margin RAPT
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-85.4% -83.7% Higher ROE VRDN
52-Week Range Position
Momentum
100% ($1–$58) 81% ($13–$34) Stronger Trend RAPT
Beta / 30D Volatility
Risk Regime
-0.02β · 2% Vol 1.13β · 65% Vol Lower Realized Risk RAPT
Unified Institutional Score
Composite Signal
52.4 / 100 (HOLD) 36.8 / 100 (SELL) Higher Composite RAPT
Trailing 12M Revenue (USD)
Operating Scale
N/A $26M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 134.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($9.02 Book/Sh · -85.4% ROE) -$353M ($70M Net Debt (0.42x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon RAPT +10.57 pp
RAPT: +0.68% · VRDN: -9.89%
3M Horizon RAPT +79.07 pp
RAPT: +74.44% · VRDN: -4.63%
6M Horizon RAPT +96.81 pp
RAPT: +101.95% · VRDN: +5.14%
1Y Horizon RAPT +96.81 pp
RAPT: +101.95% · VRDN: +5.14%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on RAPT vs VRDN. Trailing 12-month operating profitability (RAPT 0.0% vs VRDN -1781.4%) and valuation multiples (RAPT N/M vs VRDN 1.0x Forward P/E) are benchmarked directly in Pillar 4 below.

RAPT ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-85.4% · N/M
VRDN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$26M
Gross MarginN/A
Op. Margin-1781.4%
ROE / Fwd P/E-83.7% · 1.0x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
RAPT UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 0.8%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact RAPT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
VRDN SURGE
5d in phase · OBV ACCUMULATION
Current IV 87.7%
IV Percentile 20th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact VRDN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
RAPT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.7B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
VRDN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.5B market capitalization and -1781.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ RAPT vs VRDN Key Questions & Quantitative Answers

As of Nov 16, 2026, Viridian Therapeutics, Inc. (VRDN) is the stronger overall head-to-head candidate over RAPT Therapeutics, Inc. (RAPT) in the Tradestie Institutional Equity Comparison Engine, winning 5–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). RAPT carries a Unified Composite Score of 52.4/100 (HOLD) at $58.02 (N/M Forward P/E, 0.0% operating margin), whereas VRDN carries 36.8/100 (SELL) at $30.36 (1.0x Forward P/E, -1781.4% operating margin). Composite vs. Pillar Nuance: While RAPT currently prints a higher short-term Unified Composite Score (52.4/100 HOLD vs. VRDN 36.8/100 SELL), VRDN captures the overall institutional head-to-head verdict (5–4 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-1781.4% vs. 0.0% operating margin) and revenue trajectory (-63.5% vs. -100.0% YoY).

VRDN leads the Growth & Scale pillar: RAPT posts -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with VRDN at -63.5% YoY revenue growth and +0.0% YoY earnings growth on $26M TTM revenue (N/A gross margin, -1781.4% operating margin). On trailing 12-month operating scale, RAPT generates N/A in USD-normalized revenue versus $26M for VRDN. In operating R&D and SG&A reinvestment, RAPT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VRDN.

VRDN screens cheaper on headline valuation multiples. RAPT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas VRDN trades at 1.0x Forward P/E, 1.0x Trailing P/E, N/M PEG, and 134.2x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RAPT (-85.4% ROE) versus VRDN (-83.7% ROE) capital efficiency.

In options market volatility and institutional positioning, RAPT carries 0.8% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.02β · 2% Vol realized risk). By comparison, VRDN carries 87.7% implied volatility (20th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a SURGE options structure phase (1.13β · 65% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.